Registry tracking frailty and aging in older adults with blood cancers
Records frailty and aging health in people aged 50 and older with blood cancers.
Key facts
- Who runs it
- University of Alabama at Birmingham
- Where
- Birmingham, United StatesSee the site
- Trial code
- Registry title
- Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
- Status
- Recruiting
- People taking part
- 5,000 people, planned
- Started
- 21 Jul 2020
- Expected to end
- 31 Dec 2027
- Type of study
- Observational
- Record updated
- 8 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 or older with a biopsy-proven blood cancer who have appointments at UAB. It builds a registry to learn about frailty and age-related problems.
- Age
- 50 years or older
- Sex
- All sexes can join. No exclusions based on gender, ethnicity or race.
- Disease stage
- A biopsy-proven blood cancer, such as multiple myeloma, AL amyloidosis, Waldenstrom's Macrogloblunemia, Hodgkin or Non-Hodgkin lymphoma, myelodysplastic syndromes, myeloproliferative neoplasm, or acute or chronic myeloid or lymphoid leukemia.
Main reasons for not taking part
- Under 50 years old
- Does not read or speak English
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patients are ≥50 years of age
- Patients have a biopsy proven diagnosis of Hematologic Malignancy (Multiple Myeloma, AL Amyloidosis, Waldenstrom's Macrogloblunemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic syndromes, Myeloproliferative Neoplasm, Acute/Chronic Myeloid Leukemia, Acute/Chronic Lymphoid Leukemia)
- Patients have appointments at UAB including if they are an inpatient or other clinic locations
Who cannot take part
- Individuals who are <50 years old
- Patients who do not read and/or speak English will not be eligible for this study as many of the questionnaires are not validated in other languages. No exclusions will be made based on gender, ethnicity or race
Where in United States
- Kirklin Clinic of UAB HospitalBirmingham, United StatesContact: Smith Giri, Dr.Taking people
About the trial
What the trial wants to find out
The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients aged ≥50y and above diagnosed with a hematologic malignancy at UAB and to gather information that would lend support for future research in this vulnerable population.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
- Plain-language title
- Registry tracking frailty and aging in older adults with blood cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 8 December 2025